Approval · Notice of Compliance 34172 · 2024
RYBELSUS: Notice of Compliance 34172
Issued October 8, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34172
- Date
- October 8, 2024
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of new strengths
Products in this notice
Medicinal ingredients
- SEMAGLUTIDE 1.5 MG per TAB
- SEMAGLUTIDE 4 MG per TAB
- SEMAGLUTIDE 9 MG per TAB